Bystander effect of antibody–drug conjugates: Fact or fiction? Review


Authors: Giugliano, F.; Corti, C.; Tarantino, P.; Michelini, F.; Curigliano, G.
Review Title: Bystander effect of antibody–drug conjugates: Fact or fiction?
Abstract: Purpose of review: Summarizing the current preclinical and clinical evidence about bystander effect of antibody–drug conjugates (ADCs) in solid tumors. Recent findings: One of the main challenges of treating solid tumors with ADCs is the heterogeneous expression of the target antigen (Ag), which however may be overcome by the so-called bystander killing effect. This unique, but still debated, feature of certain ADCs is represented by the unintentional payload diffusion from Ag-positive tumor cells to adjacent Ag-negative tumor cells. Some pharmacological characteristics, such as a hydrophobic payload or a cleavable linker, seem to play a major role in this effect. Summary: Abundant preclinical evidence of the bystander effect has emerged, and the clinical activity of ADCs in tumors with a heterogeneous Ag expression suggests the relevance of this feature. Additional studies are required to investigate if the bystander effect is necessary for achieving a solid activity with ADCs. © 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Keywords: antineoplastic agents; antineoplastic agent; neoplasm; neoplasms; bystander effect; antibody conjugate; immunoconjugates; trastuzumab emtansine; humans; human; sacituzumab govitecan; trastuzumab deruxtecan; antibody–drug conjugates; bystander effect (cell)
Journal Title: Current Oncology Reports
Volume: 24
Issue: 7
ISSN: 1523-3790
Publisher: Springer  
Date Published: 2022-07-01
Start Page: 809
End Page: 817
Language: English
DOI: 10.1007/s11912-022-01266-4
PUBMED: 35305211
PROVIDER: scopus
DOI/URL:
Notes: Review -- Export Date: 1 July 2022 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors